Abstract
Purpose :
To compare the efficacy of rebamipide 2% and diquafosol 3% eyedrops in dry eye disease with a short tear break-up time (tBUT).
Methods :
120 eyes from 60 patients who had been diagnosed with dry eye disease were retrospectively enrolled. 30 patients (group 1, 60 eyes) were treated with rebamipide 2%, and 30 patients (group 2, 60 eyes) were treated with diquafosol 3%. The Ocular Surface Disease Index Questionnaire (OSDI), Schirmer I test, noninvasive tBUT (NItBUT), corneal and conjunctival staining score, impression cytology, and goblet cell density were examined before treatment and at 1 and 3 months after treatment.
Results :
All dry eye signs and symptoms of both groups at 1 and 3 months were significantly improved compared with those before treatment, respectively (P<0.05). There were no statistically significant differences between the two groups according to OSDI, NItBUT, corneal and conunctival fluorescein score, MMP-9 grade, goblet cell density, and impression cytology grade changes from baseline at 1 and 3 months after treatment (P > 0.05). Schirmer I change from baseline in group 2 (1.65 ± 0.57 mm) was significantly improved compared with group 1 (0.87 ± 0.46) at 3 months after treatment (P<0.05).
Conclusions :
Both rebamipide and diquafosol eyedrops were effective for relieving dry eye signs and symptoms. But diquafosol eyedrops secrete aqueous tears more than rebamipide eyedrops.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.